Loading…
Labcorp Holdings Inc. is projected to rise to $312.95 by 2027, a +13% move from its current price of $276.81. LH is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $273.67 | $276.82 | $280.00 | 0.00% |
| Jul 15 | $272.39 | $276.83 | $281.34 | +0.01% |
| Jul 16 | $271.41 | $276.84 | $282.38 | +0.01% |
| Jul 17 | $270.59 | $276.85 | $283.26 | +0.01% |
| Jul 18 | $269.87 | $276.86 | $284.03 | +0.02% |
| Jul 19 | $269.22 | $276.87 | $284.74 | +0.02% |
| Jul 20 | $268.63 | $276.88 | $285.39 | +0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $268.63 | $276.88 | $285.39 | +0.03% |
| Week 2 | $265.35 | $276.95 | $289.06 | +0.05% |
| Week 3 | $262.88 | $277.02 | $291.93 | +0.08% |
| Week 4 | $260.82 | $277.10 | $294.38 | +0.10% |
| Week 5 | $259.03 | $277.17 | $296.57 | +0.13% |
| Week 6 | $257.43 | $277.24 | $298.57 | +0.16% |
| Week 7 | $255.98 | $277.31 | $300.43 | +0.18% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Labcorp Holdings Inc. provides laboratory services and operates through two segments: Diagnostics Laboratories and Biopharma Laboratory Services. The company offers a broad suite of tests, including blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests.
It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women’s health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, the company offers digital pathology solutions, a pathology platform that supports the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI-enabled Test Selection. It serves clients including Medicare/Medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, CROs.
The company has strategic collaborations with the Children’s Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics, and with Alliance for Clinical Trials in Oncology to advance national clinical trials for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
Labcorp Holdings Inc., ticker LH, is a healthcare services company focused on in vitro diagnostics and related clinical testing. It currently trades at $279.58 per share and has a market capitalization of $22.93B, ranking 532 by market size. The current price sits within a forecast path that shows growth potential over the coming decades.
In 2026, the forecasted average price is $279.58 with a 2026 min of $250.39 and a max of $342.93, and an overall-neutral sentiment for that year. By 2030, the average price is projected to be $480.00 with a 71.7% ROI and a bullish outlook. The 2040 forecast envisions an average of $1,044.60 with a 273.6% ROI and a bullish sentiment, rising further to an average of $2,190.86 with a 683.6% ROI by 2050.
The path shows rising confidence and upside potential across multiple years while sentiment shifts toward bullish in the later periods.
A major floor 13.2% below — a decisive break under it would weaken the trend.
The nearest floor, 8.1% below — buyers have tended to step in here.
The nearest ceiling, 3.7% above — a clean break opens room to run.
A major ceiling 10.3% above — clearing it would confirm fresh momentum.
Key LH support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LH market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $280.09 | Sell | $278.79 | Sell |
| MA 10 | $280.23 | Sell | $277.54 | Sell |
| MA 20 | $271.17 | Buy | $273.40 | Buy |
| MA 50 | $263.34 | Buy | $268.10 | Buy |
| MA 100 | $267.48 | Buy | $266.77 | Buy |
| MA 200 | $267.35 | Buy | $264.73 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.32 | Neutral |
| Stoch RSI (14) | 51.86 | Neutral |
| CCI (20) | 41.47 | Neutral |
| Williams %R (14) | -31.24 | Info |
| MACD (12,26,9) | 0.45 | Buy |
| ROC (12) | 7.05 | Buy |
| Bollinger %B (20,2) | 0.64 | Neutral |
| Stochastic %K (14) | 68.76 | Neutral |
| TRIX (15) | 0.26 | Buy |
| Awesome (5,34) | 13.02 | Buy |
| Ultimate (7,14,28) | 52.89 | Neutral |
| Momentum (10) | 10.47 | Buy |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 277.38 | Sell |
| ADX (14) | 20.60 | Buy |
| ATR (14) | 2.88 | Info |
The 30-day technical picture is bullish, with RSI14 at 70 and a positive tilt. The 50-day simple moving average sits at $261.07 and the 200-day simple moving average at $267.18, signaling an upward trend. Immediate support is at $250.40 and resistance at $279.58, with the 30-day price range spanning from $256.87 to $304.29.
Annualized volatility stands around 20%, indicating a meaningful, but manageable, level of near-term fluctuation.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $250.39 | $276.81 | $333.90 | 0% | Neutral | |
| $256.33 | $312.95 | $399.46 | +13% | Neutral | |
| $261.27 | $324.98 | $426.05 | +17% | Neutral | |
| $302.77 | $382.42 | $512.03 | +38% | Bullish | |
| $362.02 | $463.44 | $631.68 | +67% | Bullish | |
| $386.14 | $500.35 | $692.78 | +81% | Bullish | |
| $425.86 | $558.05 | $783.66 | +102% | Bullish | |
| $432.38 | $572.57 | $814.47 | +107% | Bullish | |
| $438.05 | $585.85 | $843.32 | +112% | Bullish | |
| $509.08 | $687.28 | $1,000.35 | +148% | Bullish | |
| $706.13 | $994.30 | $1,516.64 | +259% | Bullish | |
| $1,354.39 | $2,045.39 | $3,344.31 | +639% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $250.39 | $276.81 | $324.37 | +0.00% |
| August 2026 | $233.53 | $273.29 | $326.71 | -1.27% |
| September 2026 | $236.18 | $277.74 | $334.65 | +1.63% |
| October 2026 | $233.76 | $276.03 | $334.79 | -0.62% |
| November 2026 | $227.65 | $269.76 | $329.00 | -2.27% |
| December 2026 | $229.12 | $272.38 | $333.90 | +0.97% |
Click any year to see its month-by-month LH forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The LH price prediction for 2026 points to an average of $276.81 (low $250.39, high $333.90) — a potential gain of 0% on today's $276.81. A consolidation phase looks the most probable path here.
In 2027, LH is projected to trade between $256.33 and $399.46, averaging $312.95 — a potential gain of +13% from today's $276.81. That is up +13% on the projected 2026 average. Price action looks broadly range-bound.
Labcorp Holdings Inc.'s 2028 outlook centres on $324.98, within a $261.27 to $426.05 range. That is up +4% on the projected 2027 average. That marks a +17% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, LH could reach as high as $512.03, with a base case around $382.42 and support toward $302.77 — roughly +38% from $276.81. Momentum favours further upside here.
Expect LH to range from $362.02 to $631.68 through 2030. The $463.44 average target implies a +67% move from current prices. That is up +21% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The LH price prediction for 2031 points to an average of $500.35 (low $386.14, high $692.78) — a potential gain of +81% on today's $276.81. Momentum favours further upside here.
In 2032, LH is projected to trade between $425.86 and $783.66, averaging $558.05 — a potential gain of +102% from today's $276.81. That is up +12% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Labcorp Holdings Inc.'s 2033 outlook centres on $572.57, within a $432.38 to $814.47 range. That is up +3% on the projected 2032 average. That marks a +107% change versus current levels. Momentum favours further upside here.
By 2034, LH could reach as high as $843.32, with a base case around $585.85 and support toward $438.05 — roughly +112% from $276.81. Buyers look set to stay in control over this stretch.
Expect LH to range from $509.08 to $1,000.35 through 2035. The $687.28 average target implies a +148% move from current prices. That is up +17% on the projected 2034 average. Momentum favours further upside here.
The LH price prediction for 2040 points to an average of $994.30 (low $706.13, high $1,516.64) — a potential gain of +259% on today's $276.81. Buyers look set to stay in control over this stretch.
In 2050, LH is projected to trade between $1,354.39 and $3,344.31, averaging $2,045.39 — a potential gain of +639% from today's $276.81. That is up +106% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in LH today (≈ 3.612586 LH) could be worth
$7,389.15
+$6,389.15 (+639%) by 2050 · US Dollar
Based on the average projected LH price of $2,045.39 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LHwould be worth at today's price.
$1,000 invested in LH on Jul 10, 2025 (≈ 3.942751 LH) would be worth
$1,091.39
+$91.39 (+9.1%) today · 1.09× · US Dollar
Based on a LH entry price of $253.63 vs. today's $276.81.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $286.98 | $964.56 | -3.5% |
| 1 month ago | $268.63 | $1,030.45 | +3.0% |
| 3 months ago | $260.93 | $1,060.86 | +6.1% |
| 6 months ago | $250.39 | $1,105.52 | +10.6% |
| 1 year ago | $253.63 | $1,091.39 | +9.1% |
| All time (5.0y) ago | $238.18 | $1,162.19 | +16.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LH forecast.
Our base-case forecast reaches $550.00 around 2032.
Implied market cap at $550.00: $45.1B
The multi-year forecast shows meaningful upside, with 2029–2035 periods setting the stage for higher prices and strong ROI. For 2030, the average price is $480.00 with a 71.7% ROI and bullish sentiment; by 2040, the average reaches $1,044.60 with a 273.6% ROI and bullish sentiment; and by 2050, the average climbs to $2,190.86 with an 683.6% ROI and bullish sentiment. Earlier among the longer horizon, 2029 is expected to average $398.18 with a 42.4% ROI, and 2031–2033 show continued gains with averages of $518.34, $583.79, and $592.21 respectively and rising ROI figures.
The forecast also shows higher potential maxima in later years, such as a 2035 max of $1,068.53 and a 2040 max of $1,593.83. Drivers include the company’s breadth of testing services, digital pathology platforms, and Generative AI-enabled Test Selection, along with strategic collaborations to advance pediatric diagnostics and national clinical trials in oncology. These are projections and not guarantees; outcomes depend on market, regulatory, and execution factors.
Tap a question to reveal the answer.
Avg $480.00; min $374.79; max $654.64; ROI 71.7%; sentiment BULLISH. These are estimates and not guarantees.
Forecasts show an upward path with 2026 average $279.58 and rising to 2030 $480.00, 2040 $1,044.60, and 2050 $2,190.86, with ROI reaching 71.7%, 273.6%, and 683.6% respectively and bullish sentiment in later years. These are estimates, not guarantees.
Yes, the 2035 max is $1,068.53 and the 2040 max is $1,593.83, indicating it could exceed $1,000 in these horizons. These are projections, not guarantees.
RSI14 is 70, sentiment is BULLISH, SMA50 is $261.07, SMA200 is $267.18, with support at $250.40 and resistance at $279.58. The 30-day range is $256.87 to $304.29, and annualized volatility is 20%.
Current price is $279.58 and market cap is $22.93B; the stock ranks 532.
Labcorp Holdings Inc. Community Discussion
0Share your Labcorp Holdings Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.